CIK 0001133416 · Non-accelerated filer<br>Smaller reporting company
GALECTIN THERAPEUTICS INC
Sign in to watch- Ticker
- GALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 043562325
- Phone
- 678-620-3186
- Business address
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 30071
- Former names
- PRO PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −13,055 | $4.20 | $55K | 46,945 |
| 2026-01-01 | CALLICUTT JACK W Chief Financial Officer | Option exercise · Restricted Stock Unit 10b5-1 | −60,000 | 0 | ||
| 2026-01-01 | Jamil Khurram Chief Medical Officer | Option exercise · Restricted Stock Unit 10b5-1 | −60,000 | 0 | ||
| 2025-12-31 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +8,125 | $1.23 | $10K | 8,125 |
| 2025-12-31 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −8,125 | $4.07 | $33K | 0 |
| 2025-12-31 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −8,125 | 40,625 | ||
| 2025-12-23 | FREEMAN KEVIN D Director | Purchase | +5,500 | $3.55 | $20K | 55,269 |
| 2025-12-23 | FREEMAN KEVIN D Director | Purchase 10b5-1 | +5,500 | $3.55 | $20K | 55,269 |
| 2025-12-23 | ELDRED KARY Director | Purchase | +700 | $3.73 | $3K | 65,382 |
| 2025-12-23 | FREEMAN KEVIN D Director | Purchase 10b5-1 | +5,500 | $3.55 | $20K | 55,269 |
| 2025-12-23 | ELDRED KARY Director | Purchase 10b5-1 | +700 | $3.73 | $3K | 65,382 |
| 2025-12-17 | LEWIS JOEL President and CEO | Option exercise 10b5-1 | +7,829 | $2.86 | $22K | 840,421 |
| 2025-12-17 | LEWIS JOEL President and CEO | Sale 10b5-1 | −7,829 | $7.06 | $55K | 832,592 |
| 2025-12-17 | LEWIS JOEL President and CEO | Option exercise · Stock option (right to buy) 10b5-1 | −7,829 | 32,171 | ||
| 2025-12-17 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −4,479 | $7.04 | $32K | 0 |
| 2025-12-17 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +6,463 | $2.20 | $14K | 6,463 |
| 2025-12-17 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −6,463 | $7.04 | $45K | 0 |
| 2025-12-17 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +8,500 | $2.50 | $21K | 8,500 |
| 2025-12-17 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −8,500 | $7.04 | $60K | 0 |
| 2025-12-17 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −6,463 | 102,037 |
Page 4 of 15 · 291 trades